ADAPY
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.12 | $14M | -$35M |
| 2025 Q1 | -0.19 | $7M | -$67M |
| 2024 Q4 | -0.29 | $3M | -$35M |
| 2024 Q3 | -0.07 | $41M | -$55M |
| 2024 Q2 | 0.27 | $128M | $47M |
| 2024 Q1 | -0.20 | $6M | -$32M |
| 2023 Q4 | -0.21 | $233,009 | -$16M |
| 2023 Q3 | -0.20 | $7M | -$45M |